Table 3.
Subgroup analysis removing patients <60 y of age with diabetes. Baseline demographic and clinical characteristics and outcomes of these patients given DMB therapy and control patients
| DMB (n = 8) | Control (n = 12) | P-value | |
|---|---|---|---|
| Baseline characteristics | |||
| Age, y, mean (SD) | 65 (2.7) | 66 (4.7) | 0.571 |
| Male, n (%) | 4 (50) | 6 (50) | 1.000 |
| Female, n (%) | 4 (50) | 6 (50) | 1.000 |
| Comorbidities, n (%) | 6 (75) | 10 (83.3) | 1.000 |
| Hypertension | 5 (62.5) | 9 (75) | 0.642 |
| Hyperlipidemia | 4 (50) | 6 (50) | 1.000 |
| CVD | 1 (12.5) | 2 (16.7) | 1.000 |
| Asthma/COPD | 2 (25) | 2 (16.7) | 1.000 |
| Stroke | 0 (0) | 0 (0) | Not estimable |
| Clinical features | |||
| Normal CXR on admission, n (%) | 2 (25) | 2 (16.7) | 1.000 |
| Time from onset of symptoms to admission, d, median (IQR) | 7 (1–10) | 5 (3–8) | 0.919 |
| Time from onset of symptom to initiation of therapy, d, median (IQR) | 7 (3–11) | ||
| Time from admission to initiation of therapy, d, median (IQR) | 1 (0–1) | ||
| Duration of therapy, d, median (IQR) | 7 (5–7) | ||
| Treatment with Kaletra/remdesivir/hydroxychloroquine, n (respective numbers),% | 2 (1/1/0), 25 | 7 (4/3/0), 58.3 | |
| Outcome | |||
| Requiring oxygen therapy (including ICU support), n (%) | 2 (25) | 7 (58.3) | 0.197 |
| - Requiring oxygen therapy (but no ICU support), n (%) | 1 (12.5) | 2 (16.7) | |
| - Requiring ICU support, n (%) | 1 (12.5) | 5 (41.7) | |
COPD, chronic obstructive pulmonary disease; CVD, cardiovascular disease; DMB, vitamin D, magnesium, vitamin B12; ICU, intensive care unit; IQR, interquartile range.